ǰÑÔ
Âѳ²°©(ovarian carcinoma)ÊÇÅ®ÐÔÉúֳϵͳ³£¼ûµÄ¶ñÐÔÖ×Áö£¬Æä·¢²¡ÂÊ¡¢²¡ËÀÂʾù¾Ó¸¾¿Æ¶ñÐÔÖ×ÁöǰÏß¡£ÏÖÔÚ½¨ÉèÂѳ²°©¶¯ÎïÄ£×ÓµÄÒªÁìÓÐ×Ô¾õÐÔµÄÂѳ²Ö×Áö¶¯ÎïÄ£×Ó¡¢ÌåÍâת»¯Âѳ²ÉÏÆ¤Ï¸°ûµÄÒÆÖ²Áö¡¢Ö°©ÎïÓÕ·¢Âѳ²Ö×ÁöÒÔ¼°»ùÒò¹¤³ÌÂѳ²Ö×Áö¶¯ÎïÄ£×Ó¡£
ÈËÂѳ²°©ÂãÊóÒÆÖ²ÁöÄ£×ÓÊǽÏΪÀíÏëµÄÂѳ²°©Ñо¿ÔØÌ壬ÔÚÈËÂѳ²°©µÄ²¡Òò¡¢·¢²¡»úÖÆ¡¢ÉúÎïѧÐÔ×´¡¢·ÅÉäÃâÒßÏÔÏñÕï¶Ï¡¢»¯ÁÆÒ©ÎïµÄɸѡ¡¢»ùÒòÖÎÁÆ¡¢ÃâÒßÖÎÁÆ¡¢¿¹Ö×ÁöÒ©ÎïµÄÑз¢µÈ·½Ãæ¶¼ÓÐÖ÷ÒªÓ¦Óá£
²¿·ÖÔìÄ£ÒªÁì
ʹÓö¯ÎÂãÊó
¡¾ÔìÄ£»úÖÆ¡¿£º
ÂãÊóÏÈÌìÐÔÐØÏÙȱʧ£¬Ï¸°ûÃâÒßȱÏÝ£¬Òò´ËÒìÌå×é֯ݪֲÓÚÆäÌåÄÚºÜÉÙ±¬·¢ÇãÔþ·´Ó¦¡£Õâ¾ÍΪÈËÖ×Áö×éÖ¯Äܹ»Îȹ̵ØÝªÖ²ÓÚÂãÊóÌåÄÚµÓÚ¨ÁËÉúÎïѧ»ù´¡¡£½ÓÄÉÈËÂѳ²°©Çгý±ê±¾¡¢ÈËÂѳ²°©Ö×Áöϸ°ûÖ꣬½ÓÖÖÓÚÂãÊóƤÏ¡¢¸¹Ç»¡¢Âѳ²£¬¿É½¨ÉèÔ´úÈËÂѳ²°©ÂãÊóÒÆÖ²ÁöÄ£×Ó¡¢ÈËÂѳ²°©ÂãÊóƤÏÂÒÆÖ²ÁöÄ£×Ó¡¢ÈËÂѳ²°©ÂãÊó¸¹Ç»ÒÆÖ²ÁöÄ£×ÓºÍÈËÂѳ²°©ÂãÊóÔÎ»ÒÆÖ²ÁöÄ£×Ó¡£
¡¾ÔìÄ£ÒªÁì¡¿£º
ʵÑ鶯Îï³£ÓÃBALB/c-nu/nuÂãÊó£¬4¡«6ÖÜÁ䣬´ÆÐÔ¡£ÊÕÂÞÈËÂѳ²°©Çгý±ê±¾£¬ÖƱ¸Ï¸°û£¬Í¨Àý×÷Óý£¬ÍøÂç¶ÔÊýÉúºã¾ÃµÄÂѳ²°©Ï¸°û£¬µ÷½âϸ°ûÃܶÈΪ5.0×107¸ö/ml£¬¸¹Ç»×¢Èë0.2ml/Ö»¡£
¡¾Ä£×ÓÌØµã¡¿£º
½ÓÖÖºó19~40Ì죬ÂãÊó·ºÆð¸¹Î§ÔöÌíÏÔ×Å¡¢¸¹²¿´¥¼°ÁöÌå¡¢Ô˶¯ïÔÌ¡¢ÏûÊݵÈÖ¢×´¡£ÍѾÊÕý·¨ÂãÊóºó£¬·¿ª¸¹Ç»£¬¿É¼û×ªÒÆµÄʵÌåÖ×Áö×éÖ¯£¬È¡Áö×éÖ¯¼°¸¹Ë®Ðв¡Àíѧ¼ì²é£¬¾µÏ¼û°©Ï¸°ûºË´ó¡¢ÉîȾ£¬¿ÉÓÐºËÆÆËéÏ󣬺ËÈÊÏÔ×Å£¬Áö×éÖ¯²¿·ÖÇøÓò¿É¼ûÄý¹ÌÐÔ»µËÀ¡£
¡¾Ä£×ӵįÀ¹ÀºÍÓ¦Óá¿£º
Ô´úÈËÂѳ²°©×éÖ¯ÒÆÖ²ÂãÊóÀÖ³ÉÂʽϵͣ¬Ô¼Îª28£¥~40£¥¡£Ò»µ©Ô´úÒÆÖ²Àֳɣ¬ÔÚ´Ë»ù´¡ÉÏÔÙÒÔ×éÖ¯¿é»òϸ°û·½·¨Êó¼ä´«´úµÄÒÆÖ²ÀÖ³ÉÂʿɵִï100%£¬ÇÒDZÔÚÆÚ±ä¶Ì£¬Ö×ÁöÉú³¤ËÙÂʸü¿ì£¬¿ÉÒÔËõ¶Ì¶¯ÎïʵÑéÖÜÆÚ¡£¸¹Ë®ÒÆÖ²Áö·´Ó¦Âѳ²°©Ï¸°ûݪֲÔÚ¸¹Ç»Éú³¤ºÍ¸¹Ë®ÐγɵÄÌØµã£¬ÔÚÒ»¶¨Ë®Æ½ÉÏÇкÏÈËÂѳ²°©µÄÁÙ´²ÌåÏÖ£¬Îª¸¹Ç»»¯ÁƵÄÒ©ÎïÑ¡ÔñºÍÉúÎïÖÎÁÆÌṩÁ˿ɿ¿µÄÑо¿ÔØÌ壬µ«ÔÚÂѳ²Éϳ£È±·¦ÊµÌåÁöµÄÌåÏÖ£¬ÇÒ¸¹Ë®ÒÆÖ²ÁöÄ£×ÓÉúÑÄʱ¼ä¶Ì£¬½üÄêÀ´Ö÷ÒªÓÃÓÚ¸¹Ç»»¯ÁÆ·ÅÉäÃâÒßÖÎÁƵÈÑо¿¡£
²Î¿¼ÎÄÏ×£º
1.Òü°®À¼£¬ÖÓ÷£¬Ëï¹ðÇÛ£¬µÈ£®ÂÌɫӫ¹âÂѰױê¼ÇµÄÈËÂѳ²°©ÂãÊóÔÎ»ÒÆÖ²Ä£×ӵĽ¨É裮ÄÏ·½Ò½¿Æ´óѧѧ±¨£¬2008,28 (3):484-486
2.ãÆÖÒöΣ¬º«·ï¾ê£¬µÔСÁú£¬µÈ£®Âѳ²°©ÂãÊóÒÆÖ²ÁöÄ£×Ó±ÈÕպͿÉÊÓ»¯Ñо¿Ï£Íû£®ÌìÏÂÖÐÎ÷ҽ͎áÔÓÖ¾£¬2012, 7 (7):636-638
3.ÇñÀö骣¬º«·ç¾ê£¬·¶ÏÔ×Å£¬µÈ£®Á½ÖÖÓÕ·¢Fischer344´óÊóÂѳ²°©¶¯ÎïÄ£×Ó½¨ÉèÒªÁìµÄ½ÏÁ¿. ÌìÏÂÖÐÎ÷ҽ͎áÔÓÖ¾£¬2010,5(6):488-490
4.Ò¦µÂÉú£®ÖØ×鷴ת¼²¡¶¾½éµ¼µÄk-Ras/c-MycСÊóÂѳ²°©¶¯ÎïÄ£×ӵĽ¨ÉèºÍÒÖ°©»ùÒòOPCMLµÄ¿Ë¡¼°ÆäÔÚÂѳ²°©ÖеĹ¦Ð§Ñо¿£®¹ãÎ÷Ò½¿Æ´óѧ²©Ê¿Ñ§Î»ÂÛÎÄ£¬2005
5.Àè¾²£¬ÍõÑ©·É£¬ÖÓ÷£®ÕûÌå¿ÉÊÓ»¯Âѳ²°©Ôλ¼°×ªÒƶ¯ÎïÄ£×ӵĽ¨É裮¹ã¶«Ò½Ñ§£¬2012, 33 (7):887-889
6.öÄȫУ¬ÃÓÈôÈ». ת»ùÒò¶¯ÎïÔÚÂѳ²Ö×ÁöÑо¿ÖеÄÓ¦Óã®ÍâÑóҽѧ¸¾²ú¿ÆÑ§·Ö²á£¬2003,30 (6):391-393
7.Connolly DC, Bao R, Nikitin AY, el al. Female mice chimeric for expression of the simian virus 40 TAg under control of the MlSilR promoter develop epithelial ovarian cancer, Cancer res 2003, 63 (6): 1389-1397
8.Dutertre M, Couédard L, Xavier F, el al. Ovarian granulosa cell tumors express a functional membrane receptor for anti-Müllerian hormone in transgenic mice. Endocri.nology, 2001, 142 (9):4040-4046
9.Carson K, Macdonald E, Dube M, et al. Generali on of tumors in transgece mice expressing the SV40 T antigen under the control of ovarian-specific promoter 1. J Soc Cynecol lnvestig,2003,10(4):244-250
10.Hoffman RM. Orthotopic metastatic (MetaMouse) models for discovery and development of novel chemotherap. Methods Mol Med,2005, 111 :297-322
11.Kananen K, Markkula M, Rainio E, et al. Gonadal tumorigenesis in transgenic mice bearing the mouse inhibin alpha-subunit promoter/simian virus T-antigen fusion gene: characterization of ovarian tumors and establishment of gonadotropin-responsive granulosa cell lines. Mol Endocrinol, 1995,9 (5):616-627
12.Selvakumaran M, Bao R, Crijns AP, el al. Ovarian epithelial cell lineage-specific gene expression using the promoter of a retrovirus-like element. Cancer Res,2001, 61 (4):1291-1295